ArticleAlzheimer's research & therapy2018
Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI).
Open access · goldAbstract read
In one paragraph
Article in Alzheimer's research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- APOE in subjective cognitive decline: a systematic review and meta-analysis.Journal of neurology · 2026Pooled it
- Cognitive and immunological effects of yoga compared to memory training in older women at risk for alzheimer's disease.Translational psychiatry · 2024Trial
- Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial.Alzheimer's research & therapy · 2023Trial
- Article
- Neuropsychiatric and neural correlates of subjective cognitive complaint.Aging clinical and experimental research · 2026Article
- An Automated Micro-Immunobeads-Based Electromagnetic Operation System (MEMOs) for Blood Testing of Alzheimer's Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study.European journal of nuclear medicine and molecular imaging · 2025Article
- DTI-ALPS index as a predictor of cognitive decline over 1 year.Neuroradiology · 2025Article
- Head-to-head comparison of tau PET tracers [Alzheimer's research & therapy · 2024Article
- Differential neuropsychiatric associations of plasma biomarkers in older adults with major depression and subjective cognitive decline.Translational psychiatry · 2024Article
- The heritability of blood-based biomarkers related to risk of Alzheimer's disease in a population-based sample of early old-age men.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Longitudinal assessment of plasma biomarkers for early detection of cognitive changes in subjective cognitive decline.Frontiers in aging neuroscience · 2024Article
- Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer's Disease-Modifying Therapy.The journal of prevention of Alzheimer's disease · 2024Article
- Predicting amyloid-beta pathology in the general population.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Changes in Multiparametric Magnetic Resonance Imaging and Plasma Amyloid-Beta Protein in Subjective Cognitive Decline.Brain sciences · 2023Article
- Leukotriene A4 hydrolase inhibition improves age-related cognitive decline via modulation of synaptic function.Science advances · 2023Article
- Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic.Translational psychiatry · 2023Article
- Bioinformatic Analysis of Human Cumulus Cells to Unravel Cellular's Processes that Could Be Used to Establish Oocyte Quality Biomarkers with Clinical Application.Reproductive sciences (Thousand Oaks, Calif.) · 2023Article
- Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.Neurology · 2022Article
- Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review.Frontiers in aging neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 2 institutions in 1 country.
Itziar de RojasResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
J RomeroAraclon Biotech©, Zaragoza, Spain.
O Rodríguez-GomezResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
P PesiniAraclon Biotech©, Zaragoza, Spain.
A SanabriaResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
A Pérez-CordonResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
C AbdelnourResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
I HernándezResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
M Rosende-RocaResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
A MauleónResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
L VargasResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
M AlegretResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
A EspinosaResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
G OrtegaResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
S GilResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
M GuitartResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
A GailhajanetResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
M A Santos-SantosResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
Sonia Moreno-GrauResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
O Sotolongo-GrauResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
S RuizResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
L MontrrealResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
E MartínResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
E PelejàResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
F LomeñaServei de Medicina Nuclear, Hospital Clínic i Provincial, Barcelona, Spain.
F CamposServei de Medicina Nuclear, Hospital Clínic i Provincial, Barcelona, Spain.
A VivasDepartament de Diagnòstic per la Imatge, Clínica Corachan, Barcelona, Spain.
M Gómez-ChiariDepartament de Diagnòstic per la Imatge, Clínica Corachan, Barcelona, Spain.
M A TejeroDepartament de Diagnòstic per la Imatge, Clínica Corachan, Barcelona, Spain.
J GiménezDepartament de Diagnòstic per la Imatge, Clínica Corachan, Barcelona, Spain.
V Pérez-GrijalbaAraclon Biotech©, Zaragoza, Spain.
G M MarquiéResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
G Monté-RubioResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
S ValeroResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
A OrellanaResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
L TárragaResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
M SarasaAraclon Biotech©, Zaragoza, Spain.
A RuizResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain. aruiz@fundacioace.org.ORCID 0000-0003-2633-2495
M BoadaResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.
FACEHBI study
Fundació ACE · ESHospital Clínic de Barcelona · ES
Funding
ARACLON FACEHBI grantGRIFOLS FACEHBI grantLaboratorios ECHEVARNE FACEHBI grantPIRAMAL AG FACEHBI grant
Abstract
backgroundPeripheral biomarkers that identify individuals at risk of developing Alzheimer's disease (AD) or predicting high amyloid beta (Aβ) brain burden would be highly valuable. To facilitate clinical trials of disease-modifying therapies, plasma concentrations of Aβ species are good candidates for peripheral AD biomarkers, but studies to date have generated conflicting results.
methodsThe Fundació ACE Healthy Brain Initiative (FACEHBI) study uses a convenience sample of 200 individuals diagnosed with subjective cognitive decline (SCD) at the Fundació ACE (Barcelona, Spain) who underwent amyloid florbetaben(
resultsFBB-PET global SUVR correlated weakly but significantly with Aβ42/40 plasma ratios. For TP42/40, this observation persisted after controlling for age and APOE ε4 allele carrier status (R
conclusionBrain and plasma Aβ levels are partially correlated in individuals diagnosed with SCD. Aβ plasma measurements, particularly the TP42/40 ratio, could generate a new recruitment strategy independent of the APOE genotype that would improve identification of SCD subjects with brain amyloidosis and reduce the rate of screening failures in preclinical AD studies. Independent replication of these findings is warranted.
Indexed as
AgedAmyloid beta-PeptidesAniline CompoundsBiomarkersBrainCognitive DysfunctionEthylene GlycolsFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedPeptide FragmentsPositron-Emission TomographyAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)Aniline CompoundsBiomarkersEthylene GlycolsflorbetapirPeptide FragmentsAlzheimer’s diseaseAmyloid βFlorbetabenPETPlasma biomarkerPreclinical ADSubjective cognitive declineTP42/40
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.